News


Mol Cell, Nat Commun, Frontiers Cell Dev Biol, Proteomics: our 5 latest publications

Category: Highlighted publications at the CRCM

MRX Increases Chromatin Accessibility at Stalled Replication Forks to Promote Nascent DNA Resection and Cohesin Loading.

Delamarre A, Barthe A, de la Roche Saint-André C, Luciano P, Forey R, Padioleau I, Skrzypczak M, Ginalski K, Géli V, Pasero P, Lengronne A.

Mol Cell. 2019 Nov 13. pii: S1097-2765(19)30807-X. doi: 10.1016/j.molcel.2019.10.029

www.ncbi.nlm.nih.gov/pubmed/31759824

 

The nuclear pore complex prevents sister chromatid recombination during replicative senescence

Aguilera P, Whalen J, Minguet C, Churikov D, Freudenreich C, Simon MN & Géli V

Nature Communications volume 11, Article number: 160 (2020)

www.nature.com/articles/s41467-019-13979-5

 

Non-canonical Roles of Telomerase: Unraveling the Imbroglio.

Ségal-Bendirdjian E, Geli V.

Front Cell Dev Biol. 2019 Dec 10;7:332. doi: 10.3389/fcell.2019.00332

www.ncbi.nlm.nih.gov/pubmed/31911897

 

Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking.

Bidan N, Bailleul-Dubois J, Duval J, Winter M, Denoulet M, Hannebicque K, El-Sayed IY, Ginestier C, Forissier V, Charafe-Jauffret E, Macario M, Matsunaga YT, Meignan S, Anquez F, Julien S, Bonnefond A, Derhourhi M, Le Bourhis X, Lagadec C.

Proteomics. 2019 Nov;19(21-22):e1800454.

www.ncbi.nlm.nih.gov/pubmed/31430054

 

The Tumor Suppressor SCRIB is a Negative Modulator of the Wnt/β-Catenin Signaling Pathway.

Daulat AM, Wagner MS, Walton A, Baudelet E, Audebert S, Camoin L, Borg JP.

Proteomics. 2019 Nov;19(21-22):e1800487.

www.ncbi.nlm.nih.gov/pubmed/31513346

 

 

 

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.

Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J, Josselin E, Macario M, Castellano R, Léonard-Stumpf C, Bal A, Gros A, Lossy S, Kharrat M, Collette Y, Bertucci F, Birnbaum D, Douik H, Bidaut G, Charafe-Jauffret E, Ginestier C.

EMBO Mol Med. 2019 Sep 2:e9930. doi: 10.15252/emmm.201809930.

www.ncbi.nlm.nih.gov/pubmed/31476112



Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine.

Lomberk G, Dusetti N, Iovanna J, Urrutia R.

Nat Commun. 2019 Aug 28;10(1):3875. doi: 10.1038/s41467-019-11812-7. 

www.nature.com/articles/s41467-019-11812-7



Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, othe F , Willard-Gallo K, Haller A, Ninane V, Burny A, Sculier JP, Spira A, Galon J

Nature. 2019 Jun 26. doi: 10.1038/s41586-019-1330-0. 

www.ncbi.nlm.nih.gov/pubmed/31243362


Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E.

JCI Insight. 2019 Jun 13;5. pii: 128180. doi: 10.1172/jci.insight.128180.

www.ncbi.nlm.nih.gov/pubmed/31194699 



Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Tran Dien A, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Tabernero J, Chia S, Martinalbo J, Perez-Moreno P, Dogan S, Verret B, Chaffanet M, Bacelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron D, Le Tourneau C & André F.

Nature 2019, doi.org/10.1038/s41586-019-1056-z  



Ligand-based design of a potent inhibitor of NUPR1 exerting anticancer activity via necroptosis

Santofimia-Catano P, Xia Y, Lan W, Zhou Z, Huang C, Peng L, Soubeyran P, Velazquez-Campoy A, Abian O, Rizzuti B, Neira JL, Iovanna JL.

Journal of Clinical Investigations 2019, doi.org/10.1172/JCI127223

www.ncbi.nlm.nih.gov/pubmed/30920390